Image For Activity Cover
Cardiovascular Disease in Myeloproliferative Neoplasms (JACC: CardioOncology State-of-the-Art Review June 2022-1)
Cardiovascular Disease in Myeloproliferative Neoplasms (JACC: CardioOncology State-of-the-Art Review June 2022-1)
Myeloproliferative neoplasms are associated with increased risk for thrombotic complications. These conditions most commonly involve somatic mutations in genes that lead to constitutive activation of the Janus-associated kinase signaling pathway (eg, Janus kinase 2, calreticulin, myeloproliferative leukemia protein). Acquired gain-of-function mutations in these genes, particularly Janus kinase 2, can cause a spectrum of disorders, ranging from clonal hematopoiesis of indeterminate potential, a recently recognized age-related promoter of cardiovascular disease, to frank hematologic malignancy. Beyond thrombosis, patients with myeloproliferative neoplasms can develop other cardiovascular conditions, including heart failure and pulmonary hypertension. The authors review the pathophysiologic mechanisms of cardiovascular complications of myeloproliferative neoplasms, which involve inflammation, prothrombotic and profibrotic factors (including transforming growth factor–beta and lysyl oxidase), and abnormal function of circulating clones of mutated leukocytes and platelets from affected individuals. Anti-inflammatory therapies may provide cardiovascular benefit in patients with myeloproliferative neoplasms, a hypothesis that requires rigorous evaluation in clinical trials.

JACC CardioOncology Editor-in-Chief and CME Editor
Bonnie Ky, MD, MSCE, FACC

Authors
Orly Leiva, MD
Peter Libby, MD

Important Dates

Date of Release: June 21, 2022     
Term of Approval/Date of CME/MOC/ECME Expiration: June 20, 2023

Summary
Availability: On-Demand
Expires on Jun 20, 2023
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By